Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-cycloserine rTMS Plasticity Enhancement in MDD
NCT03511599Phase 1Completed
- Sponsor
- University of Calgary
- Start
- Sep 2018
- Primary completion
- Dec 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of d-cycloserine in major depressive disorder (MDD) (2 arms), sponsored by University of Calgary. Primary endpoint: Motor evoked potential amplitude. Started Sep 2018; status: completed.
02
Drugs
d-cycloserine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03511599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03511599.